炎症性腸疾患へのアフェレシスの新展開 : 難治性クローン病患者への適応拡大(<特集>アフェレシスの新しい適応をめぐって)

概要

論文の詳細を見る
Extracorporeal leukocyte removal therapy (LRT), including filtration leukocytapheresis, centrifugal lymphocytapheresis, and granulocyte/monocyte adsorption apheresis (GMA), is an adjunct therapeutic strategy and has been accepted by the government's health insurance policy for refractory ulcerative colitis (UC) patients in Japan. Furthermore, in 2009, immune-adsorptive GMA has been also accepted by the policy for Crohn's disease (CD), another major form of inflammatory bowel disease (IBD). The present report aimes to review the current and the future prospective of LRT, a brand-new therapeutic option in Japan, for CD. In the era of anti-cytokine therapy, LRT could be expected to have the potential to establish an independent stand-point in the field of therapeutic strategy for refractory CD patients so as to induce and maintain their sustained remission utilizing not only its clinical efficiency, but also its safe characteristics.
2010-10-31